Epcoritamab With Lenalidomide and Tafasitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL)
Latest Information Update: 15 Jul 2025
At a glance
- Drugs Epcoritamab (Primary) ; Lenalidomide (Primary) ; Tafasitamab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Lymphoma
- Focus Therapeutic Use
- Acronyms ECLAT
Most Recent Events
- 04 Jul 2025 Planned initiation date changed from 30 Jun 2025 to 1 Jul 2025.
- 26 Jun 2025 New trial record